ABT-492 Size:2mg solid 2) with lower affinity

2) with lower affinity

N-4-Tosyl-L-arginine methyl ester

dBET6 features highly increased cellular potency with evident degradation in the sub-nanomolar range

with no apparent toxicity

administered twice a day by oral gavage for 9-12 days) reduces ex vivo sickling and prolongs red blood cells (RBCs) half-life in a murine model of sickle cell disease (SCD)

ABT-492 Size:2mg solid 2) with lower affinityABT 492 is a non zwitterionic fluoroquinolone antibiotic under development for for the treatment of respiratory and skin infections. Delafloxacin demonstrates excellent antibacterial potency and exhibits a low probability for the selection of resistant mutants in MRSA. Although mutants can be selected at low frequencies in vitro from quinolone resistant isolates, delafloxacin MICs and MPCs remain low and a fitness cost can be observed. Consequently